Evidence map›Paper›PMID 40045152›Full record

SynthesisAmerican journal of clinical dermatology2025

Real-World Evidence of Tralokinumab Effectiveness and Safety: A Systematic Review and Meta-analysis.

Amalie Thorsti Møller Rønnstad, Christopher G Bunick, Raj Chovatiya, Masahiro Kamata, Mia-Louise Nielsen, Daniel Isufi, Simon F Thomsen, Christian Vestergaard, Andreas Wollenberg, Alexander Egeberg and 2 more

Erratum issuedAbstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in American journal of clinical dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Amalie Thorsti Møller RønnstadDepartment of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.
Christopher G BunickProgram in Translational Biomedicine, Yale School of Medicine, Yale University, New Haven, CT, USA.
Raj ChovatiyaChicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA.
Masahiro KamataDepartment of Dermatology, Teikyo University School of Medicine, Tokyo, Japan.
Mia-Louise NielsenDepartment of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.
Daniel IsufiDepartment of Dermatology and Allergy, Copenhagen University Hospital-Herlev and Gentofte, Copenhagen, Denmark.
Simon F ThomsenDepartment of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.
Christian VestergaardDepartment of Dermatology, Aarhus University Hospital, Aarhus, Denmark.
Andreas WollenbergDepartment of Dermatology and Allergy, University Hospital Augsburg, Augsburg, Germany.
Alexander EgebergDepartment of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.
Jacob P ThyssenDepartment of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.
Nikolai LoftDepartment of Dermatology and Allergy, Copenhagen University Hospital-Herlev and Gentofte, Copenhagen, Denmark. nikolai.nguyen.loft@regionh.dk.ORCID http://orcid.org/0000-0002-2950-3280

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTralokinumab, a first-in-class and second biologic approved for treating moderate-to-severe atopic dermatitis in adolescents and adults, has demonstrated consistent efficacy and safety across multiple clinical trials.

objectiveWe aimed to assess the real-world effectiveness and safety of tralokinumab by performing a systematic review and meta-analysis on the real-world evidence of tralokinumab.

methodsWe systematically searched PubMed and EMBASE from inception until 28 July, 2024 for observational studies describing the effectiveness and safety of tralokinumab for the treatment of atopic dermatitis. The primary outcome was the proportion of patients achieving a ≥75% improvement in the Eczema Area and Severity Index (EASI-75) after 16 weeks and secondary outcomes included the proportion of patients achieving EASI-50 and EASI-90 and the proportion of patients experiencing adverse events.

resultsNineteen unique studies encompassing 911 bio-naïve and bio-experienced patients with atopic dermatitis treated with tralokinumab were included. After 16 weeks of treatment, 82%, 59% and 26% of patients achieved EASI-50, EASI-75 and EASI-90, respectively, and the proportion of patients developing conjunctivitis was 3.2%.

conclusionsTralokinumab demonstrates strong effectiveness and good tolerability in real-world settings, with a high proportion of patients achieving a clinical response and adverse events being observed only infrequently.

Indexed as

Antibodies, MonoclonalDermatitis, AtopicDermatologic AgentsConjunctivitisHumansObservational Studies as TopicSeverity of Illness IndexTreatment OutcomeAntibodies, MonoclonalDermatologic Agentstralokinumab

Identifiers

PMID40045152

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.